Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Diluted EPS of $0.04 per share (loss) for fiscal year 2023.
AXIM BIOTECHNOLOGIES, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$0.04 | +0.0% |
| 2022 | -$0.04 | -133.3% |
| 2021 | $0.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | -$0.01 | +50.0% | -900.0% |
| March 31, 2024 | -$0.00 | +90.0% | -242.9% |
| September 30, 2023 | $0.00 | +105.8% | +103.5% |
| June 30, 2023 | -$0.02 | -100.0% | -100.0% |
| March 31, 2023 | -$0.01 | +0.0% | +16.7% |
| September 30, 2022 | -$0.01 | +40.0% | -20.0% |
| June 30, 2022 | -$0.01 | +66.7% | +0.0% |
| March 31, 2022 | -$0.01 | +0.0% | +50.0% |
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, AXIM BIOTECHNOLOGIES, INC.’s diluted eps has declined by 133.3% (from $0.12 per share to $0.04 per share (loss)).
- The most recent figure is from AXIM BIOTECHNOLOGIES, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: